Mantle Cell Lymphoma Market

View All

Breaking Ground: Ibrutinib and Venetoclax Synergy Delivers Significant Progression-Free Survival Boost in Relapsed/Refractory Mantle Cell Lymphoma

Date of Abstract presentation12th December 2023IndicationsMantle Cell Lymphoma (MCL)Abstract NumberLBA-2Abstract typeOral Ibrutinib, an oral BTK inhibitor, holds approval in numerous countries for the treatment of R/R MCL. Similarly, venetoclax, an oral BCL2 inhibitor, has gained approval in multiple countries f...

Find More